Antibiotic drugs | Serotype 2 59 strains | Non-serotype 2 73 strains | Autoagglutinating 91 strains | Non-typable 39 strains | P-value | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S | I | R | S | I | R | S | I | R | S | I | R | ||
AMP | 58 (98.3%) | 1 (1.7%) | 0 (0%) | 50 (68.5%) | 6 (8.2%) | 17 (23.3%) | 56 (61.5%) | 13 (14.3%) | 22 (24.2%) | 28 (71.8%) | 5 (12.8%) | 6 (15.4%) | <  0.001* |
CFL | 58 (98.3%) | 0 (0%) | 1 (1.7%) | 41 (56.2%) | 4 (5.5%) | 28 (38.3%) | 46 (50.5%) | 0 (0%) | 45 (49.5%) | 20 (51.3%) | 1 2.6%) | 18 (46.1%) | <  0.001* |
CTX | 58 (98.3%) | 0 (0%) | 1 (1.7%) | 65 (89.0%) | 2 (2.7%) | 6 (8.3%) | 88 (96.7%) | 1 (1.1%) | 2 (2.2%) | 33 (84.6%) | 1 2.6%) | 5 (12.8%) | 0.078 |
CTF | 58 (98.3%) | 0 (0%) | 1 (1.7%) | 69 (94.5%) | 1 (1.4%) | 3 (4.1%) | 88 (96.7%) | 1 (1.1%) | 2 (2.2%) | 33 (84.6%) | 3 (7.7%) | 3 (7.7%) | 0.053 |
PEN | 57 (96.6%) | 1 (1.7%) | 1 (1.7%) | 22 (30.1%) | 34 (46.6%) | 17 (23.3%) | 26 (28.5%) | 35 (38.5%) | 30 (33.0%) | 14 (35.9%) | 17 (43.6%) | 8 (20.5%) | <  0.001* |
VAN | 59 (100%) | 0 (0%) | 0 (0%) | 69 (94.6%) | 2 (2.7%) | 2 (2.7%) | 90 (98.9%) | 1 (1.1%) | 0 (0%) | 35 (89.8%) | 2 (5.1%) | 2 (5.1%) | 0.972 |
AZM | 5 (8.5%) | 0 (0%) | 54 (91.5%) | 8 (11.0%) | 0 (0%) | 65 (89.0%) | 16 (17.6%) | 3 (3.3%) | 72 (79.1%) | 11 (28.2%) | 1 (2.6%) | 27 (69.2%) | 0.063 |
CHL | 53 (89.8%) | 6 (10.2%) | 0 (0%) | 61 (83.6%) | 5 (6.8%) | 7 (9.6%) | 83 (91.2%) | 1 (1.1%) | 7 (7.7%) | 32 (82.1%) | 5 (12.8%) | 2 (5.1%) | 0.032* |
CLI | 5 (8.5%) | 0 (0%) | 54 (91.5%) | 4 (5.5%) | 0 (0%) | 69 (94.5%) | 3 (3.3%) | 0 (0%) | 88 (96.7%) | 5 (12.8%) | 0 (0%) | 34 (87.2%) | 0.187 |
DOX | 0 (0%) | 0 (0%) | 59 (100%) | 8 (11.0%) | 1 (1.4%) | 64 (87.6%) | 11 (12.1%) | 2 (2.2%) | 78 (85.7%) | 5 (12.8%) | 2 (5.1%) | 32 (82.1%) | 0.078 |
ERY | 4 (6.8%) | 5 (8.5%) | 50 (84.7%) | 8 (11.0%) | 1 (1.4%) | 64 (87.6%) | 19 (20.9%) | 1 (1.1%) | 71 (78.0%) | 12 (30.8%) | 0 (0%) | 27 (69.2%) | 0.002* |
FFC | 52 (88.1%) | 1 (1.7%) | 6 (10.2%) | 70 (95.9%) | 0 (0%) | 3 (4.1%) | 85 (93.4%) | 0 (0%) | 6 (6.6%) | 36 (92.3%) | 1 (2.6%) | 2 (5.1%) | 0.443 |
GEN | 33 (55.9%) | 8 (13.6%) | 18 (30.5%) | 26 (35.6%) | 17 (23.3%) | 30 (41.1%) | 25 (27.5%) | 28 (30.7%) | 38 (41.8%) | 16 (41.0%) | 8 (20.5%) | 15 (38.5%) | 0.027* |
TET | 0 (0%) | 0 (0%) | 59 (100%) | 2 (2.7%) | 3 (4.1%) | 68 (93.2%) | 6 (6.6%) | 1 (1.1%) | 84 (92.3%) | 5 (12.8%) | 3 (7.7%) | 31 (79.5%) | 0.023* |
TIA | 1 (1.7%) | 30 (50.8%) | 28 (47.5%) | 2 (2.7%) | 8 (11.0%) | 63 (86.3%) | 1 (1.1%) | 4 (4.4%) | 86 (94.5%) | 2 (5.1%) | 3 (7.7%) | 34 (87.2%) | <  0.001* |
CIP | 47 (79.6%) | 7 (11.9%) | 5 (8.5%) | 38 (52.1%) | 12 (16.4%) | 23 (31.5%) | 50 (54.9%) | 10 (11.0%) | 31 (34.1%) | 20 (51.3%) | 7 (17.9%) | 12 (30.8%) | 0.008* |
ENR | 32 (54.2%) | 27 (45.8%) | 0 (0%) | 38 (52.1%) | 13 (17.8%) | 22 (30.1%) | 55 (60.4%) | 9 (9.9%) | 27 (29.7%) | 18 (46.1%) | 7 (17.9%) | 14 (35.9%) | <  0.001* |
NOR | 15 (25.4%) | 27 (45.8%) | 17 (28.8%) | 17 (23.3%) | 18 (24.6%) | 38 (52.1%) | 21 (23.1%) | 20 (22.0%) | 50 (54.9%) | 12 (30.8%) | 8 (20.5%) | 19 (48.7%) | 0.203 |
LEV | 59 (100%) | 0 (0%) | 0 (0%) | 48 (65.8%) | 4 (5.5%) | 21 (28.7%) | 67 (73.6%) | 1 (1.1%) | 23 (25.3%) | 28 (71.8%) | 1 (2.6%) | 10 (25.6%) | <  0.001* |
SXT | 46 (78.0%) | 2 (3.4%) | 11 (18.6%) | 22 (30.1%) | 3 (4.1%) | 48 (65.8%) | 16 (17.6%) | 2 (2.2%) | 73 (86.2%) | 11 (28.2%) | 3 (7.7%) | 25 (64.1%) | <  0.001* |